Accession Number:



Mesenchymal Stem Cells for Treatment of ARDS Following Trauma

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

CALIFORNIA UNIV REGENTS SAN FRANCISCOZuckerberg San Francisco General Hospital and Trauma CenterUniversity of Harborview Medical CenterOregon Health and Science UniversityUniversity of Texas Health Sciences Center at Houston/Memorial HermannVanderbilt University Medical Center

Report Date:


Pagination or Media Count:



The acute respiratory distress syndrome ARDS is a life-threatening medical condition in which the lung is injured or inflamed to the degree that it cannot properly exchange gases and oxygenate the body. ARDS can be caused by a variety of conditions including trauma, severe blood loss, multiple or large volume blood transfusions, burns, and infections. The development of therapeutics that can limit the severity andor progression of lung injuries that lead to ARDS and death is an immediate clinical need in both military and civilian sectors. Experimental studies carried out in small and large animals have demonstrated that specialized cells called mesenchymal stromal cells MSC can effectively reduce inflammation in multiple diseases including ARDS. The overall objective of this proposal is to carry out a randomized, blinded, placebo-controlled, multicenter phase 2b trial to test the therapeutic potential of allogeneic bone-marrow derived MSC for treating ARDS, with a major focus on civilian trauma patients. The specific aims of this project are Specific Aim 1. To test the clinical efficacy of intravenously delivered allogeneic human MSC in patients with ARDS. Specific Aim 2. To test the mechanisms by which MSC reduce acute lung injury in patients with ARDS.


Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

[A, Approved For Public Release]